Posttraumatic stress disorder after cancer diagnosis in adults:a meta-analysis by Swartzman, Samantha et al.
                                                              
University of Dundee
Post-traumatic stress disorder after cancer diagnosis in adults
Swartzman, Samantha; Booth, Josephine; Munro, Alastair; Sani, Fabio
Published in:
Depression and Anxiety
DOI:
10.1002/da.22542
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Swartzman, S., Booth, J., Munro, A., & Sani, F. (2017). Post-traumatic stress disorder after cancer diagnosis in
adults: a meta-analysis. Depression and Anxiety, 34, 327-339. DOI: 10.1002/da.22542
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 07. Nov. 2017
1 
Samantha Swartzman 
Post-traumatic stress disorder after cancer diagnosis in adults: A 
meta-analysis  
Short title: Meta-analysis on PTSD after cancer diagnosis 
Samantha Swartzman, BA, MSc, MBPsS 
School of Social Sciences, Scrymgeour Building, Park Place, University of Dundee, Dundee, 
DD1 4HN 
Telephone: (+44) (0)1382 388254 
Email: s.g.swartzman@dundee.ac.uk 
Josephine N. Booth, PhD, CPsychol 
School of Social Sciences, Scrymgeour Building, Park Place, University of Dundee, Dundee, 
DD1 4HN 
Telephone: (+44) (0)1382 384187 
Alastair Munro, BSc, FRCR, FRCP(E) 
Tayside Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, 
Dundee, DD1 9SY 
Telephone: +(44) (0)1382 496491 
Fabio Sani, BA, MSc, PhD 
School of Social Sciences, Scrymgeour Building, Park Place, University of Dundee, Dundee, 
DD1 4HN 
Telephone: (+44) (0)1382 384628 
Key words: 
Stress Disorders, Post-Traumatic 
Neoplasms 
Review, Systematic 
Meta-Analysis 
Epidemiology 
The authors have no financial interests to declare. 
This is the peer reviewed version of the following article: Post-traumatic stress disorder after cancer 
diagnosis in adults,  et. al., which has been published in final form at 10.1002/da.22542. This article 
may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for 
Self-Archiving.
2 
Samantha Swartzman   
Abstract 
BACKGROUND: Since the introduction of serious illness as a potential traumatic stressor in 
the fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 
research on the prevalence and predictors of post-traumatic stress disorder (PTSD) after 
cancer diagnosis has proliferated. Studies have reported widely varying estimates of the 
number of people with PTSD after cancer. The aim of this review is to synthesize 
quantitative data from studies reporting the proportion of people with PTSD among groups of 
cancer survivors. METHODS: We undertook a diversified literature search strategy and 
identified 120 samples from 110 sources reporting a proportion of cancer survivors with 
PTSD. Of these, eleven studies, containing twelve samples, reported estimates of PTSD in 
cancer survivors compared to matched controls. RESULTS: A random effects meta-analysis 
estimated the odds ratio as 1.66 (95% confidence interval: 1.09 to 2.53) for PTSD in cancer 
survivors compared to controls, although some of this apparent increase may have arisen 
from publication bias. Factors influencing the reported proportion of a post-cancer sample 
with PTSD included measurement type (clinical interview vs. self-report instrument), type of 
cancer, type of treatment, geographic region, whether the term “post-traumatic stress” was in 
the title or abstract, prior trauma, age, and time since diagnosis. CONCLUSIONS: PTSD, 
diagnosed according to DSM-IV criteria, is more common in survivors of cancer than it is in 
the general population. Estimates of the occurrence of PTSD in patients with a history of 
cancer depend upon clinical and demographic factors, as well as upon study design. 
  
3 
Samantha Swartzman   
Introduction 
Psychological distress and morbidity may be triggered or exacerbated by a cancer 
diagnosis. Along with financial problems, role reversals, and the physical consequences of 
treatment [1-3], cancer survivors face a variety of psychological sequelae of their disease, 
including loneliness and fear of recurrence [4; 5]. Although much attention has focused on 
depression and anxiety after cancer diagnoses, a recent systematic review found that cancer 
survivors have no increased risk of depression and only 1.27 times the relative risk of anxiety 
compared to control participants [6]. 
 Cancer may cause psychological morbidity in the form of post-traumatic stress 
disorder (PTSD). PTSD is said to arise from an inadequate cognitive processing of trauma 
memories [7]. Symptoms include: re-experiencing during flashbacks or intrusive thoughts; 
avoidance of trauma memories coupled with emotional numbing; hyperarousal symptoms, 
such as an exaggerated startle response [8]. A diagnosis of serious illness was listed as one 
potential traumatic stressor in the fourth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) [8]. Cancer fits both of the DSM-IV criteria for a traumatic stressor; 
it is life-threatening and may trigger “intense fear, horror, and helplessness” [8]. Newer 
DSM-5 criteria focus on the medium and duration of the trauma while excluding any 
characterization of its subjective experience, but according to the DSM-5, a medical illness 
such as cancer is only considered a traumatic event when it is “sudden” and “catastrophic” 
[9]. Furthermore, there have been a number of changes to the formulation of a PTSD 
diagnosis in DSM-5 which might impact on its applicability within a cancer setting; for 
instance, the three symptoms described in the DSM-IV have now been divided into four, 
including a new category of “negative cognitions.”  
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 Apart from this, there are a number of conceptual issues surrounding the inclusion of 
cancer within a traumatic stress framework. As Kangas et al. [10], Smith et al. [11], and 
Gurevich et al. [12] discuss, the cancer experience may involve multiple traumatic events 
over the course of diagnosis and treatment, some of which are complex and repeated. 
Furthermore, cancer may be considered an “internal” threat, rather than an external threat 
from, for example, attackers or natural disasters [10; 12; 13]. Whether an internal threat to 
one’s health can function as a trauma is controversial. Gurevich et al. [12] and Mehnert and 
Koch [14]  argue that some of the most distressing aspects of the cancer experience are those 
that involve uncertainty or a fear of potential death in the future, rather than discrete external 
traumatic events taking place in the past; nevertheless, Mehnert et al. [14] also found that 
diagnosis itself, a discrete event, is often perceived as traumatic.  
Furthermore, some of the symptoms of PTSD, such as a loss of concentration or 
insomnia, may be attributable to cancer or its treatment [10; 12]. As Smith et al. [11] discuss, 
cancer also differs from other types of traumatic stressors in that its “threat,” or risk of pain, 
death, or injury, varies considerably from case to case. Rustad et al. [15] have recently 
highlighted the concern that cancer itself causes generalized distress in the forms of sadness, 
anger, and worry and that these symptoms are conflated with PTSD [13]. Another concern is 
that factor structures of PTSD scales in cancer populations have not always conformed to the 
three-factor structure of PTSD [15]. One study found numbing and avoidance as separate 
symptoms, inconsistent with DSM-IV symptomatology, and weak factor loadings [16]. 
However, other studies from non-cancer settings have also found a four-factor structure for 
PTSD scales (e.g., [17; 18]). Therefore, there is significant debate as to whether cancer 
conforms to the traditional picture of a trauma causing PTSD. 
 In the literature, the proportion of cancer survivors with PTSD has varied widely, 
from 36-45% of ovarian cancer survivors [19] to 6% of breast cancer survivors [20]. 
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Andrykowski and Cordova [21] found that time since the end of treatment, stage of cancer at 
diagnosis, and psychosocial factors such as social support predict levels of PTSD. Other 
studies have since confirmed that sources of this variation may include clinical factors such 
as time since diagnosis [22] and stage of disease [23] or demographic factors such as age [24] 
and gender [25].  
Family members or caregivers of cancer survivors may also experience negative 
psychosocial outcomes, such as anxiety and depression [26; 27]. Family caregivers of cancer 
patients have a poorer quality of life than cancer patients themselves [28]. Ell et al. [29] 
found that individuals close to cancer survivors were still experiencing distress related to the 
cancer a year after their family member’s diagnosis. Smith [11] found that parents of cancer 
survivors have a greater risk of PTSD than their children. These studies are concordant with a 
systemic approach to illness, which assumes that the cancer experience takes place within a 
social system of delicate dynamics and interrelationships [30]. In line with this literature, we 
decided to include studies sampling family members and caregivers of cancer survivors in 
our review. 
 This review contributes to the debate about whether cancer can function as a 
traumatic stressor by identifying factors significantly affecting the reported proportion of a 
post-cancer diagnosis sample with PTSD, expressed as a percentage. We also calculate the 
relative likelihood of PTSD in cancer survivors compared to controls without cancer. We 
assessed current PTSD, rather than lifetime PTSD, as studies investigating the latter were 
uncommon. This review includes studies applying DSM-IV or International Classification of 
Diseases (ICD) version 10 criteria for PTSD to adult cancer survivors at any stage of disease, 
from one month after diagnosis to many years after treatment has ended. DSM-IV and ICD-
10 criteria for PTSD are closely related, including the same three symptom clusters, although 
the ICD-10 criteria require the traumatic event to be likely to cause “pervasive distress in 
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almost anyone” [31] while DSM-IV criteria require “fear, horror, and helplessness” [8; 32]. 
We have applied “Preferred reporting items for systematic reviews and meta-analyses” 
(PRISMA) guidelines [33] and the “Meta-analysis of observational studies in epidemiology” 
(MOOSE) guidelines [34]. 
Methods 
Literature search strategies 
The first stage of the literature review process was to query three databases: MedLine 
via PubMed, the Published International Literature on Traumatic Stress (PILOTS) database 
via ProQuest, and PsycInfo via ProQuest. All databases were searched using a combination 
of free text key words and controlled vocabulary terms (for example, MeSH) for two 
concepts: cancer and post-traumatic stress disorder. The full search strategy for the MedLine 
search is given in Table 1.  
[Table 1] 
We searched within one journal in particular, Psycho-Oncology, for all articles 
containing the term “post-traumatic stress” or its variants. From the papers identified using 
these methods, we created a list of authors who had contributed multiple papers. We 
contacted these authors for citations that we might have excluded. Authors were asked to 
advise us of any well-known papers as well as rare or unpublished papers, in order to address 
the “file drawer” problem. We identified a subset of highly relevant papers and conducted 
backward and forward literature searches, searching reference lists and the ISI Web of 
Knowledge cited reference search function. To identify grey (or “fugitive”) literature, we also 
searched an online database called OpenGrey. The systematic review protocol can be 
obtained from the first author. All papers published before ICD-10 and DSM-IV criteria were 
published in 1994 were excluded. Literature indexed after mid-2013 was excluded, as newer 
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DSM-5 criteria came into force after that point. Where there was an option to include specific 
subheadings of a search term, we included all possible subheadings. A PRISMA flowchart 
demonstrating the search process can be found in Figure 1. Papers were assessed for 
eligibility using the inclusion criteria in Table 2. 
[Figure 1] 
[Table 2] 
Quality assessment 
We undertook quality assessment of included papers using Loney et al.’s [35] criteria 
for the assessment of epidemiological studies. This eight-item checklist assesses criteria 
relating to the selection of the sample, the measurement of the outcome, and the description 
of the results. As most of the studies identified for this review were retrospective or cross-
sectional cohort studies, none met all eight criteria. Quality scores are shown in the quality 
criteria table, Supplementary Materials 3. No study adjusted for known risk factors for PTSD, 
such as age or gender [24; 25].  
In addition to this formal quality assessment, we focused on potential sources of bias 
in estimates of PTSD proportion; for instance, we excluded papers that sampled from support 
groups and other settings for which the proportion of PTSD would be exaggerated, since 
seeking help is associated with greater severity of mental health problems [36; 37]. Twelve 
papers were excluded based on this criterion. These papers sampled from among participants 
pre-screened for high or low PTSD or depression scores; those identified by clinicians as 
having high levels of distress; those referred to or seeking counseling, psychology, or support 
services; and groups of participants with known psychiatric illness. 
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Data extraction 
Information extracted from studies meeting inclusion criteria included: number of 
people with PTSD; sample size; PTSD measurement instrument; type of cancer; type of 
treatment; stage of cancer; mean time since diagnosis in months; country; gender; mean age 
of sample; whether the study was peer-reviewed or not; reliability of PTSD instrument; 
whether the sample included survivors or family members/caregivers; ethnicity; prior trauma; 
whether the PTSD was explicitly linked to cancer; or whether “post-traumatic stress” or any 
variant were included in the title or abstract of the paper. This list of variables was derived 
from previously identified risk factors [12]. For papers reporting estimates of PTSD in cancer 
survivors compared to non-cancer controls, we also extracted the number of people with 
PTSD in the non-cancer group and the size of this group. When only abstracts were available, 
we contacted authors for further information and extracted all information possible from 
abstracts. 
Authors were contacted for missing data if the papers did not report the number of 
people with PTSD. For longitudinal studies, we included only the latest data point available 
for all papers in order to take advantage of the longer latencies between diagnosis and PTSD 
assessment. This also allowed us to avoid double-sampling participants. If papers reported 
two methods of assessing PTSD, we included only the results from clinical interviews rather 
than self-report measures. Where authors reported time since the end of treatment, we added 
six months to derive an approximation of the time since diagnosis. Where medians rather 
than means were given, the data were considered missing. 
Statistical procedures 
We conducted random effects meta-analysis using Comprehensive Meta-Analysis 2.0 
(Englewood, NJ, 2005) and Stata version 14.1 (StataCorp 4905 Lakeway Dr College Station, 
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TX 7784). We used random effects rather than fixed effects because, in this case, it was 
reasonable to assume that the proportion of survivors with PTSD would not be uniform 
across all studies. We used the DerSimonian-Laird [38] estimator for between-study variance. 
We calculated I2 to determine the amount of heterogeneity [39]. For studies comparing cancer 
survivors to controls with no cases of PTSD in the control group, 0.25 was added to the 
denominator of the odds ratio to avoid a denominator of 0. All subgroup analyses were 
planned according to our pre-specific protocol. 
Factors affecting proportion of PTSD 
Since the log proportion effect sizes represent single values, and not a comparison of values, 
investigation of variables influencing effect sizes would not appropriately be called 
“moderator analysis.” However, we sometimes refer to it as such because this is the normal 
usage in meta-analyses. We conducted mixed-effects moderator analysis and “method of 
moments” (random effects) meta-regression to determine factors affecting the proportion of 
people with PTSD in a sample. Potential “moderators” included PTSD assessment tool (self-
report or clinical interview), type of cancer, type of treatment, stage of disease, time since 
diagnosis, global region, gender of sample, mean age of sample, whether the study was peer-
reviewed or not, and the relationship of participants to the survivor (in samples of family 
members). In response to literature asserting that self-report measures overinflate estimates of 
PTSD, we extracted information about type of PTSD measurement instrument and conducted 
moderator analyses to identify differences between measurement instruments in terms of 
PTSD proportion.   
Reliability analysis 
Reliability analysis was conducted both for study selection and data extraction. A second 
coder was asked to apply inclusion criteria to 10% of screened papers and determine whether 
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they were eligible for this study; agreement was 93.8%. The two discrepancies were due to 
one of the coders missing information from the articles. A second coder was also asked to 
extract data from 10% of all studies included in the analysis. Of 108 items extracted, the 
coders agreed on 102 (94.4%) of items. Four of these discrepancies were due to the second 
coder missing information in the papers. 
Results 
Description of studies 
We identified 120 samples from 110 studies meeting inclusion criteria. These studies 
included 16,755 participants, 1,812 of whom were diagnosed with PTSD according to 
individual study procedures for assessing PTSD, equivalent to an overall absolute proportion 
of 10.8%. Proportion of the sample with PTSD ranged from 0% to nearly 52%. 
Hematological, breast, prostate, colorectal, gynecological, brain, and head and neck cancers 
were represented. The majority of studies were conducted in North America. The authors of 
an additional 70 papers were contacted for missing data, but were either unable to provide 
data or did not respond to our request for missing data. A table of all included studies and full 
reference information is shown in Supplementary Materials 1. Estimates of PTSD proportion 
in ascending order along with their confidence intervals are shown in Figure 2.  
[Figure 2] 
Publication bias was assessed using a plot of the observed PTSD proportion and the 
standard error of the estimate, as shown in Figure 3. This indicates the presence of bias, as 
the less powerful the study, the higher the reported proportion of PTSD. For further 
discussion of bias, please see Supplementary Materials 2. 
[Figure 3] 
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Summary odds ratio 
Of the 110 studies meeting eligibility criteria, eleven studies (twelve samples) 
included a comparison group. We used random effects meta-analysis on this subset of twelve 
samples to calculate log odds ratios for PTSD for cancer survivors compared with controls 
who had no history of cancer. The summary odds ratio was 1.66 (95% CI: 1.09, 2.53). The Q 
test for heterogeneity was not significant; I2 was 17.2%, indicating that relatively little 
variability between studies was attributable to heterogeneity. A forest plot illustrating effect 
sizes for each study and confidence intervals can be found in Figure 4. Odd ratios comparing 
occurrence of PTSD in cancer survivors compared to non-cancer controls are generally larger 
than 1, indicating a higher likelihood of PTSD among cancer survivors.  
[Figure 4] 
In addition, we calculated the rate difference between non-cancer controls and cancer 
survivors. The summary rate difference was 6.2% (95% confidence interval 1.6% to 10.8%), 
although analyses of bias, as described in Supplementary Materials 2, indicate that this 
estimate of difference may be inflated. A forest plot of the rate differences can be found in 
Figure 5. A funnel plot demonstrating publication bias affecting these twelve comparison 
studies is shown in Figure 6. 
[Figures 5 and 6] 
Factors affecting reported proportion of sample with PTSD 
The above odds ratio reflects the relative likelihood of PTSD among cancer survivors 
compared to controls without a history of cancer. We also conducted analyses to determine 
the factors affecting the raw proportion of cancer survivors with PTSD within each sample. 
The following analyses are based on all studies that reported sufficient information on these 
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variables. Since not all studies reported on all potential factors, the numbers included in each 
separate analysis may differ. 
Measurement instrument 
Eighty-two studies reported the proportion of PTSD as assessed by self-report 
measures and 31 assessed this figure through clinical interviews. Type of measurement 
instrument (clinical interview compared to self-report measure) had a significant effect on 
proportion of cancer survivors reporting PTSD (Q(1) = 24.8, p <0.001). The percentage of 
people with PTSD assessed using clinical interviews was 4.0% (95% CI: 2.6%, 6.2%), while 
the percentage of people with PTSD assessed using self-report measures was 12.8% (95% CI: 
10.8%, 15.0%).  
Type of cancer 
 We also performed moderator analysis to determine whether type of cancer 
significantly influenced PTSD proportion. Moderator analysis indicated that there was a 
significant difference in terms of PTSD proportion across cancer types (Q(6)=16.2, p = 
0.013). Table 3 below shows the summary proportion of the sample with PTSD for each type 
of cancer. However, the number of studies may skew results; for instance, there is only one 
study reporting on head and neck cancers, which reported a relatively low percentage of 
PTSD cases. 
[Table 3] 
Type of treatment 
Moderator analysis indicated that there was a significant difference in terms of PTSD 
proportion across types of treatment (Q(3)=13.3, p = 0.004). Table 4 below shows the 
summary proportion estimate for each type of treatment. 
[Table 4] 
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Geographic region 
There was a significant difference in terms of PTSD proportion depending on the 
region where the data were collected (Q(3)=68.9, p < 0.001). Table 5, below, shows the 
summary proportion estimate for each geographic area. 
[Table 5] 
Whether “post-traumatic stress” was in the title or abstract 
We extracted data regarding whether “post-traumatic stress,” PTSD, or any other 
variant of the term was in the title or abstract of the paper. Summary proportions of the 
sample with PTSD were significantly higher among those papers that did contain these terms 
in the title (Q(1) = 17.8, p < 0.001). Papers containing these terms in the title or abstract 
reported a proportion of PTSD of 12.2% (95% CI: 10.4, 14.2) compared to studies that did 
not contain these words in the title or abstract, which reported a summary proportion of 2.8% 
(95% CI: 1.4, 5.5).  
Prior trauma 
One hundred fourteen studies reported estimates of PTSD among samples that had not 
experienced a prior trauma, and six papers reported estimates of PTSD among cancer 
survivors who had experienced a prior trauma. PTSD estimates were significantly higher 
among the samples who had experienced a prior trauma (Q(1) = 6.1, p = 0.014). Proportion 
with PTSD of the samples of survivors who had experienced a trauma prior to cancer was 
19.4% (95% CI: 11.7, 30.4). Among the samples who had not experienced a prior trauma, the 
summary proportion of PTSD was 9.9% (95% CI: 8.4, 11.6).  
Age 
Mixed effects (“method of moments”) meta-regression demonstrated that the mean 
age of the sample was significantly related to log proportion with PTSD. Among papers 
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reporting higher mean sample ages, proportion of sample with PTSD was lower. The slope of 
this relationship was calculated from raw, rather than logit, proportions. The slope indicated 
that, for each additional year increase in the mean age of a group, PTSD estimates would be 
predicted to decrease by 0.3%. 
Time since diagnosis 
Mixed effects meta-regression also demonstrated that time since diagnosis was 
negatively related to log proportion. Among papers that reported longer latencies between 
diagnosis and data collection, PTSD proportion was lower. As above, the slope of this 
relationship was calculated from raw proportions. The slope indicated that, for each 
additional year after diagnosis, PTSD percentage within a sample would decrease by 0.5%. 
Factors that did not influence proportion of PTSD 
No other variables significantly influenced proportion of the sample with PTSD. This 
includes stage, gender of sample (where the gender was entirely male or female), and 
whether or not the study was reported in a peer-reviewed journal. Family members/caregivers 
of relatives with cancer survivors did not differ from cancer survivors themselves in terms of 
the proportion of the sample with PTSD. Forty-nine studies specifically assessed PTSD 
related to cancer, and these did not differ significantly in terms of proportion with PTSD 
from studies which did not explicitly link PTSD to the cancer experience.  
Discussion 
This systematic review and meta-analysis assessed the relative likelihood of PTSD 
among cancer survivors compared to controls and the factors influencing the proportion of 
cancer survivors with PTSD. Among the twelve comparative studies we found, cancer 
survivors seem to have 1.66 times the odds of PTSD compared to controls who have not had 
cancer. In many of these studies, control participants were potentially traumatized as well, 
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with some having non-malignant disease [e.g., 25] or having siblings with cancer [40]. This 
may imply that this study underestimates the odds ratio. Publication bias might, however, 
have a countervailing effect, as shown in the analyses of bias in Supplementary Materials 2. 
The results of this meta-analysis should be interpreted in light of the recent changes to 
the PTSD diagnosis described in the DSM-5 [9]. The DSM-5 no longer includes medical 
illness as a potential traumatic event, but the present meta-analysis shows that, at least 
according to the earlier DSM-IV criteria for PTSD, cancer survivors and people close to them 
may have post-traumatic stress related to their illness. There are several studies cited in this 
review that used clinician-administered diagnostic interviews to assess PTSD as specifically 
related to cancer. These results call into question any clear delineation between a “traumatic” 
event and a merely “upsetting” event. However, it is also relevant to note that cancer 
survivors may still meet criteria for “adjustment disorder.” Akechi et al. [41] have shown that 
the prevalence of adjustment disorder among cancer survivors exceeds that of PTSD; Hund et 
al. [42] estimate this prevalence at 12.4%. Therefore, it is a matter of ongoing controversy 
whether the category of adjustment disorder, rather than post-traumatic stress disorder, better 
describes cancer survivors’ experiences after their disease. 
Our results must be interpreted in light of the broader range of changes made to the 
PTSD diagnosis within DSM-5 [9]. According to DSM-5, medical illness no longer counts as 
a traumatic event, and the subjective criteria of “fear, horror, and helplessness” are no longer 
necessary. However, DSM-5 PTSD also requires a different constellation of symptoms; for 
instance, while DSM-IV required avoidance and emotional numbing symptoms, DSM-5 
requires avoidance symptoms as separate from a new category of symptoms referred to as 
“negative cognitions.” Kangas [43] discusses the implications of these changes for future 
diagnoses of PTSD among a cancer population, showing that the DSM-5 criteria for PTSD 
may not readily apply to cancer survivors, as many of their negative cognitions are related to 
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future-oriented worries and concerns rather than memories of the past. Therefore, the 
prevalence of DSM-5 PTSD among cancer survivors is uncertain. 
It is important to mention that our meta-analysis compared the proportion of people 
with PTSD within varying post-cancer samples across different factors, but these proportions 
do not easily translate into overall prevalence figures. To determine the overall prevalence of 
PTSD among cancer survivors, we would need to have synthesized data from across large, 
population-based epidemiological studies. Unfortunately, few such studies exist. However, 
many studies reported a raw proportion of the total sample with PTSD; these are the figures 
that we have synthesized in our review and the types of papers that we included. Given the 
variations in quality and representativeness of these studies, this paper is a step towards 
understanding the factors that influence these raw proportions of PTSD among diverse cancer 
samples, but it cannot establish an overall figure for the prevalence, at the population level, of 
PTSD after a diagnosis of cancer. 
Our study had several limitations. First of all, a high number of potentially eligible 
studies were excluded because of missing data. This was partly due to the fact that many 
studies were nearly twenty years old, and in many cases data were not retained for such a 
long period. Furthermore, this study provides a synthesis of proportion of cancer survivors 
with PTSD, since that was the measure of PTSD most frequently reported. As a result, the 
studies included in this review assessed current PTSD rather than lifetime PTSD. We found 
very few studies assessing lifetime risk of cancer-related PTSD. Therefore, the above results 
may be taken as an indication of how many cancer survivors are currently living with PTSD, 
but it does not tell us how many cancer survivors have ever had PTSD or how many cancer 
survivors are likely to experience PTSD at any time after diagnosis. Furthermore, few studies 
assessed the impact of traumas in the period intervening between diagnosis and the 
measurement of PTSD symptoms, although our finding that proportion with PTSD decreases 
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as time since diagnosis increases suggests that participants did not experience many traumas 
in this period.  
Relatedly, most of the studies included in this review were cross-sectional; few 
studies were prospective or longitudinal. This is important because cross-sectional studies 
such as those included in our review cannot give likely timeframes for the development of 
PTSD nor, as described by Kangas et al. [10], can they illuminate its potential course. Our 
results, in part, reflect a lack of prospectively designed studies. Therefore, our results reflect 
the likelihood of having PTSD at specific points after diagnosis based on different variables, 
but not the cumulative likelihood of developing PTSD after diagnosis. In addition, although 
many studies linked post-traumatic stress directly to the cancer experience, for some others, it 
was not clear whether PTSD was present before the cancer diagnosis. This may be seen as a 
limitation of the study, because this implies that some cases of PTSD might have been 
present before a cancer diagnosis. However, the proportion of the sample with PTSD did not 
seem to differ among papers indexing PTSD directly to the cancer experience and papers for 
which this was unclear. We believe that this is because many studies in the latter category 
did, in fact, index PTSD to the cancer experience, although this linkage was not formally 
reported. 
There may be interactions between variables considered separately in this analysis. 
For example, as above, three papers reported very high estimates of PTSD after 
chemotherapy. However, these studies used self-report measures, and a fourth study on PTSD 
after chemotherapy as assessed by clinical interview reported a much lower figure. It is 
difficult to determine whether the higher figures are attributable to chemotherapy or to the 
use of self-report measures. From this collection of cross-sectional studies, it is difficult to 
determine whether or not such measurement error has occurred in this analysis. Related to 
this point, it is also the case that there were often unequal numbers of studies reporting on 
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different levels of moderator variables. This is a common occurrence in meta-analysis, as 
papers occur in varying frequency in the literature. However, in our study this may constitute 
a limitation, as it is unclear whether, for instance, the three studies reporting on PTSD after 
radiotherapy are representative.  
We expected that clinical variables, such as type of cancer and stage of disease, would 
be particularly important in determining the proportion of cancer survivors with PTSD. Our 
results indicate that there are significant differences in terms of PTSD proportion across 
cancer types, but this result should be interpreted with caution, given that some types of 
cancer are under-represented. For instance, 38 studies (over half of the studies specifying a 
particular type of cancer) reported on PTSD after breast cancer, but only one study reported 
on PTSD after head and neck cancer. Colorectal cancers, the third most common cancer in 
both men and women in the United Kingdom [44], are represented by only two studies. 
Therefore, there seems to be a disproportionate focus on breast cancer in the literature on 
post-traumatic stress, and more research is required to determine whether PTSD figures vary 
across cancer types. 
PTSD proportion also differed by type of treatment. Surgery seemed to be associated 
with a lower proportion of PTSD after cancer diagnosis; this may be because, in some cases, 
radical surgery can remove cancer without the need for more invasive treatments. However, 
chemotherapy was associated with a greater proportion of PTSD. One explanation for this 
may be that chemotherapy can cause chronic or repeated toxicity rather than the more 
immediate and acute pattern of distress associated with surgery. The DSM-5 [9] emphasizes 
that repeated or continuous traumas may trigger post-traumatic stress in the same way as 
sudden, unexpected traumas. In line with this, chemotherapy may act as a prolonged 
reminder of cancer and its implications, and for this reason may be associated with a higher 
incidence of PTSD.  
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Another anomalous finding was that stage of cancer did not affect PTSD proportion. 
Cancers caught early are more curable and less threatening, objectively, than cancers 
diagnosed at more advanced stages. This is particularly relevant in light of recent changes to 
the diagnostic criteria of PTSD for the DSM-5 [9], which has eliminated the criteria that a 
trauma cause subjective “fear, horror, and helplessness.” However, in contradiction to that, 
our results indicate that stage, an objective indicator of threat, is not associated with PTSD 
proportion. This implies that subjective appraisals of the trauma may be important in 
determining levels of post-traumatic stress, as was also found by Mehnert et al. [14]. 
There is debate as to whether self-report measures are sufficiently robust to be used as 
diagnostic tools for PTSD. On one hand, self-report scales such as the Post-traumatic Stress 
Checklist (PCL) have shown acceptable functionality as screening tools for PTSD [45; 46]. 
However, more recently, evidence has emerged that self-report measures overestimate the 
proportion of people reporting PTSD  [47]. In response, some researchers (e.g., [48; 49]) 
have used self-report measures to assess post-traumatic stress symptomatology or generalized 
cancer-related distress, without using cut-offs for a PTSD diagnosis.  Our results indicate that 
participants who use self-report measures are roughly three times more likely to meet criteria 
for PTSD than are those assessed using diagnostic interviews. This supports the view that 
self-report measures, while potentially useful indicators of symptomatology, should be used 
with caution as diagnostic tools, particularly in patients treated for cancer. 
Older participants were less likely to have PTSD, which is consistent with literature 
on older age and post-traumatic stress [50]. Female participants did not have a higher 
proportion of PTSD, in contrast to previous reports [51]. This may have to do with the fact 
that few studies reported separate proportion figures for each gender, so we were unable to 
detect such differences. Additionally, some have argued that symptoms of PTSD persists 
over time, and that they are not necessarily a part of “natural” recovery [7]. Our results 
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suggest that the proportion of a sample with PTSD may be lower in studies sampling further 
from diagnosis, although the proportion does not fall to zero over time. Finally, groups of 
participants who had had a prior trauma were more likely to report PTSD, as has been 
reported previously in the literature [52]. 
We were unable to explore the effect of ethnicity upon cancer-associated PTSD as 
very few studies reported figures separately for each ethnic group. Anecdotally, we note that 
many studies reporting the ethnic breakdown of their samples reported percentages of 
Caucasian participants in excess of 80%. A recent study [53] has indicated that ethnicity may 
be an important risk factor for the development of cancer-related PTSD, but this study was 
ineligible for our review because it used the Impact of Events Scale, a measure that does not 
include all symptoms of post-traumatic stress disorder. Given evidence that marginalized 
groups may be disproportionately affected by trauma [54], we believe this topic requires 
further empirical investigation. 
Estimates of the proportion of a sample with PTSD depended on several factors 
related to the context within which studies were performed and published. Studies conducted 
in Asia reported lower levels of PTSD, while studies conducted in the Middle East (mostly 
Israel) reported higher levels of PTSD. These differences may be attributable to cultural 
differences or to differing diagnostic practices; it is not clear from our study what the source 
of these differences is. Estimates of the proportion of PTSD were not significantly different 
between published studies that had been peer reviewed (n = 99) and those that had not (n = 
21). However, studies containing the words “post-traumatic stress” were significantly more 
likely to report a higher proportion of PTSD, a possible example of confirmation bias. 
 Relatives and caregivers of cancer survivors had PTSD in similar proportions to 
cancer survivors themselves. This finding is concordant with other studies that have shown 
that relatives and caregivers are equally, if not more, affected by the cancer experience [e.g., 
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55]. This finding is also interesting in light of the fact that the etiology of PTSD may be 
different for cancer survivors than it is for their significant others. According to the DSM-IV 
[8], an event triggering a PTSD diagnosis involves “a threat to the physical integrity of self or 
others.” In the case of family members of cancer survivors, their PTSD is associated with 
traumas that are vicariously, rather than directly, experienced. Despite the difference in 
triggers between cancer survivors and their family members, PTSD proportions did not seem 
to differ between these two groups. This strengthens the argument, informed by a systemic 
approach to illness [30], that family members are closely involved in their loved one’s illness. 
However, the recent changes to the DSM-5 indicate that close friends and family members of 
cancer survivors cannot have PTSD related to their loved one’s cancer, as “indirect exposure” 
can only be considered under a traumatic stress framework if the trauma is “violent or 
accidental” [9]. Our results conflict with this assertion, showing that close friends and family 
members can meet criteria for PTSD even if their exposure to the trauma is indirect, at least 
according to DSM-IV criteria. 
Our study suggests several directions for future research. Firstly, as above, further 
research establishing PTSD figures across a broader variety of cancer types would be useful, 
as research on patients with breast cancer and gynecological cancer is currently over-
represented. Research on ethnicity and socioeconomic status as predictors of cancer-related 
PTSD is also sparse. However, these research agendas may be stymied by new DSM-5 
guidelines that exclude cancer as a potential traumatic event. Further conceptual analysis of 
cancer-related PTSD in light of these changes should be undertaken, whether this involves 
deconstructing the current criteria for PTSD, or whether researchers in this area must shift 
focus onto the category of “adjustment disorder” rather than PTSD. 
Conclusion 
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Cancer survivors are at increased risk of post-traumatic stress disorder, as defined according 
to the DSM-IV criteria for PTSD. Synthesis of the twelve eligible comparison studies shows 
that cancer survivors have 1.66 times the odds of PTSD compared to controls with no history 
of cancer. The rate difference between the two groups is 6.2%. There is little heterogeneity 
amongst the papers contributing to the estimate of odds ratio. This finding is noteworthy 
given the controversy surrounding the inclusion of cancer within a traumatic stress 
framework and the fact that cancer is no longer officially considered a traumatic event 
according to the DSM-5 [9]. Nevertheless, psychologists or other professionals providing 
psychosocial services should be aware of this increased risk of PTSD among cancer 
survivors. Younger patients, those who have had chemotherapy, and those seen sooner after 
diagnosis may be particularly vulnerable. Relatives and loved ones may also suffer from 
PTSD as often as cancer survivors themselves. Finally, cancer-related trauma may be 
complicated by an internal locus of threat and future-oriented cognitions, which may 
influence the clinical pattern of the PTSD. 
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Tables 
Table 1. Full electronic search strategy for MedLine via PubMed 
(post-traumatic stress disorder[TIAB] OR posttraumatic stress disorder[TIAB] OR post 
traumatic stress disorder[TIAB] OR PTSD[TIAB] OR stress disorders, post-traumatic[MH]) 
AND (neoplasms[MH] OR cancer*[TIAB] OR neoplas*[TIAB] OR malignan*[TIAB] OR 
oncolog*[TIAB] OR tumour*[TIAB] OR tumor*[TIAB])  
Filter: Adults 19+ 
 
Table 2: Inclusion and exclusion criteria for papers 
Inclusion criteria Exclusion criteria 
Studies included in this review: 
 
1. Original reports of empirical research 
 
2. Studies assessing post-traumatic stress 
disorder among cancer survivors who 
were older than 18 at diagnosis or their 
caregivers/relatives 
 
3. Studies assessing PTSD at least one 
month after diagnosis 
 
4. Studies using validated instruments 
reflecting DSM-IV or International 
Classification of Diseases (ICD) version 
10 criteria for PTSD 
 
5. Studies published between 1994 (when 
DSM-IV criteria were published) and 
2013 (when DSM-IV criteria were 
replaced) 
 
6. Studies written in the English language 
Studies excluded from this review: 
 
1. Case studies or review articles 
 
2. Studies reporting on PTSD among 
children younger than 18 or their relatives 
 
3. Studies that were likely to oversample 
survivors with PTSD, such as studies that 
sampled survivors from support groups 
 
4. Articles assessing post-traumatic stress 
symptoms outside of the DSM-IV or 
ICD-10 definitions, or failing to assess all 
such symptoms 
 
Table 3: Summary proportion (%) of samples with PTSD after cancer diagnosis, shown by 
type of cancer 
Type of cancer Number of Summary proportion with PTSD (95% 
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studies CI) 
Brain 3 17.4 (8.0, 33.9) 
Breast 38 10.0 (8.0, 12.5) 
Colorectal 2 4.3 (0.4, 31.0) 
Gynaecological 15 13.2 (8.1, 20.9) 
Head and neck 1 0.3 (0.0, 2.3) 
Haematological 9 10.4 (6.8, 15.4) 
Prostate 4 9.8 (3.4, 25.4) 
 
Table 4: Summary proportion (%) of samples with PTSD after cancer diagnosis, shown by 
type of treatment 
Type of treatment Number of 
studies 
Summary proportion with PTSD (95% 
CI) 
Chemotherapy 4 27.0 (13.0, 47.7) 
Radiotherapy 3 14.6 (6.8, 28.7) 
Stem cell transplant 11 11.8 (8.5, 16.2) 
Surgery 13 5.6 (3.3, 9.3) 
 
Table 5: Summary proportion (%) of samples with PTSD after cancer diagnosis, shown by 
geographic region 
Region Number of 
studies 
Summary proportion with PTSD (95% 
CI) 
Asia 7 2.2 (0.4, 10.3) 
Europe 28 9.1 (6.4, 12.7) 
Middle East 6 26.3 (22.4, 30.7) 
North America 50 9.1 (7.0, 11.9) 
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Figure legends 
Figure 1: PRISMA flowchart 
 
Figure 2. Proportions with PTSD and confidence intervals from 120 included studies, both 
comparative and non-comparative 
 
Figure 3. A plot of standard error by proportion with PTSD, demonstrating publication bias 
in 120 samples, both comparative and non-comparative 
 
Figure 4. Forest plot illustrating odds ratios, confidence intervals, and overall summary odds 
ratio  representing the likelihood of PTSD after cancer diagnosis compared to non-cancer 
controls 
 
Figure 5. Forest plot illustrating rate differences, confidence intervals, and overall summary 
rate difference, comparing cancer survivors to controls without cancer 
 
Figure 6: Funnel plot demonstrating publication bias in 12 samples comparing estimates of 
PTSD proportion among cancer survivors to controls who have not had cancer 
 
 
